Factory Supply Pharmaceutical Vorinostat Pure 99% Chemical Powder Vorinostat
Product Description
Product Details
| Product Name |
Vorinostat |
| Apperance |
white powder |
| CAS |
149647-78-9 |
| MF |
C14H20N2O3 |
| MW |
264.3202 |
Vorinostat is a novel molecular targeted anti-tumor drug that causes cell cycle arrest and/or apoptosis by inhibiting histone deacetylase (HDAC). It is the first HDAC inhibitor approved by the US FDA for the treatment of cutaneous T-cell lymphoma (CTCL) with obvious skin invasion that has progressed, developed drug resistance or relapsed after two systemic treatment regimens.
On October 6, 2006, the U.S. Food and Drug Administration (FDA) approved vorinostat capsules as a new drug for the treatment of skin cancer. This drug is the world's first novel anti-cancer drug developed by Merck of the United States that inhibits histone deacetylase. It is used to treat cutaneous T-cell lymphoma (CTCL). The FDA has approved its use for metastatic cutaneous T-lymphoblastoma in cases where it cannot be cured, worsens, or recurs after treatment with other drugs. A large number of experimental studies and clinical results have shown that vorinostat has a good therapeutic effect on various tumors. When combined with other tumor drugs, it has a significant synergistic effect. Currently, the treatment research on other tumors is still deepening. These results indicate that vorinostat has broad market prospects.
Vorinota has low toxicity. The evidence for its safety and efficacy comes from two clinical trials, including 107 patients with CTCL who relapsed after receiving treatment with other drugs. Based on the standard analysis determined by the improvement of the skin injury score grade, 30% of the patients treated with Zolinza showed improvement, and the therapeutic effect lasted for an average of 168 days. The most common serious adverse reactions are pulmonary embolism, dehydration, deep venous thrombosis and anemia. Common adverse reactions include gastrointestinal symptoms (including diarrhea, nausea, loss of appetite, vomiting and constipation); Fatigue, chills and taste disorders. The results of animal experiments show that this drug is contraindicated for pregnant women.
Application&Function
Preparation method
Octanoic acid undergoes intramolecular dehydration under the action to form octanoic anhydride. It then undergoes ring-opening amidation with at 0 ° C to obtain monoacyl octanoic acid. After esterification and amination with hydroxylamine hydrochloride, the anti-tumor drug volinostat is obtained, with a total yield of approximately 65%.
The anti-cancer drug vorinostat can clear out the latent HIV virus
A pioneering research paper published by researchers from the University of North Carolina at Chapel Hill in the United States in the journal Nature on July 25, 2012 It has been confirmed that a deacetylase inhibitor drug that can be used to treat certain types of lymphoma - vorinostat - can clear the latent HIV virus in patients' bodies.
Researchers conducted a series of experiments to evaluate the potential of this drug to activate and destroy the latent HIV virus. Initially, laboratory experiments measuring the level of active HIV virus in CD4+ T cells indicated that vorinostat removed the disguise of latent HIV virus in these cells. Then, eight men with HIV infection who remained medically stable after antiretroviral therapy took vorinostat, and the levels of active HIV in their bodies were tested and compared with those before taking the drug.
Researchers found that the level of HIV viral RNA in CD4+ T cells of these patients treated with vorinota increased by an average of 4.5 times, thereby confirming that the HIV virus had lost its disguise. This is the first published study to confirm that deacetylase inhibitors have the potential to break through the latency in the latent viral pool. This study provides compelling evidence suggesting that people may adopt a new strategy to directly attack and eradicate latent HIV virus infections. Breaking the latency of the HIV virus is only the first step in curing HIV infection.
Specification
ABOUT US
){kind=link}